VRDN Valuation
Viridian Therapeutics Inc
$
12.800
- Overview
- Forecast
- Valuation
VRDN Relative Valuation
VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRDN is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for VRDN's competitors is 985.50, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 5907.58, which is 499.45% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
VBTX
Veritex Holdings Inc
24.970
USD
-0.56%
MMI
Marcus & Millichap Inc
29.280
USD
-1.45%
ENFN
Enfusion Inc
10.990
USD
-0.37%
SPNS
Sapiens International Corporation NV
28.310
USD
-0.81%
BLX
Foreign Trade Bank of Latin America Inc
39.800
USD
+0.45%
LADR
Ladder Capital Corp
10.595
USD
-0.52%
SRCE
1st Source Corp
62.230
USD
-0.19%
LEG
Leggett & Platt Inc
9.200
USD
-3.66%
STBA
S&T Bancorp Inc
38.120
USD
-0.73%
ACDC
ProFrac Holding Corp
6.360
USD
+3.75%
FAQ
Is Viridian Therapeutics Inc (VRDN) currently overvalued or undervalued?
Viridian Therapeutics Inc (VRDN) is now in the Fair zone, suggesting that its current forward PS ratio of 5907.58 is considered Fairly compared with the five-year average of 2324.60. The fair price of Viridian Therapeutics Inc (VRDN) is between 5.93 to 16.39 according to relative valuation methord.
What is Viridian Therapeutics Inc (VRDN) fair value?
How does VRDN's valuation metrics compare to the industry average?
What is the current P/B ratio for Viridian Therapeutics Inc (VRDN) as of May 19 2025?
What is the current FCF Yield for Viridian Therapeutics Inc (VRDN) as of May 19 2025?
What is the current Forward P/E ratio for Viridian Therapeutics Inc (VRDN) as of May 19 2025?